Literature DB >> 33643891

A Novel Insight Into Fecal Occult Blood Test for the Management of Gastric Cancer: Complication, Survival, and Chemotherapy Benefit After R0 Resection.

Jun Lu1,2,3, Binbin Xu1,2,3, Yu Xu4, Yuan Wu4, Jianwei Xie1,2,3, Jiabin Wang1,2,3, Jianxian Lin1,2,3, Qiyue Chen1,2,3, Longlong Cao1,2,3, Chaohui Zheng1,2,3, Changming Huang1,2,3, Ping Li1,2,3.   

Abstract

BACKGROUND: Previous studies have shown that the all-cause mortality and non-colorectal cancer mortality of patients with fecal occult blood test (FOBT) positivity are significantly increased, implying that FOBT results may have more prognostic value.
METHODS: Retrospective analysis was performed for gastric cancer (GC) patients who underwent R0 gastrectomy from July 2007 to July 2014 at our hospital. Propensity score matching (PSM) was used to reduce confounding bias and a computerized technique for the nearest available score matching without replacement was applied. The cumulative survival rate was calculated using the Kaplan-Meier method and a log-rank test. Cox proportional hazards regression and logistic regression was used to determine the independent prognostic factors associated with survival and postoperative complications, respectively. The expression level of tumor-associated macrophages (TAMs) and proinflammatory cytokines (TNF-α, IL-6) were evaluated by immunohistochemical (IHC).
RESULTS: A total of 3,003 patients were included and 246 patients (8.2%) were in preoperative FOBT positive status. There was no significant difference in demographic data between preoperative FOBT positive and negative group after a 1:4 PSM. The overall postoperative complications, major complications, and anastomotic leakage were significantly higher in the preoperative FOBT-positive group than in the preoperative FOBT-negative group. Moreover, preoperative FOBT-positivity was an independent risk factor for 5-year overall survival (OS) (HR: 1.32, p = 0.005). For stage II/III patients, the postoperative adjuvant chemotherapy (PAC) benefit was found in preoperative FOBT-negative group (5-year OS: 49.9 vs. 36.8%, p = 0.001), whereas the PAC benefit was lost in preoperative FOBT-positive groups (5-year OS: 40.8 vs. 37.7% p = 0.896). Finally, IHC found that preoperative FOBT-positivity in patients was significantly associated with higher TAMs infiltration and higher expression of IL-6 and TNF-α in tumor tissues than in the preoperative FOBT-negative group.
CONCLUSION: As a simple and low-cost method, preoperative FOBT results can predict both complications and survival after R0 gastrectomy for GC. More importantly, stage II/III GC patients with FOBT-positive seem not benefit from PAC alone. Further exploration is warranted.
Copyright © 2021 Lu, Xu, Xu, Wu, Xie, Wang, Lin, Chen, Cao, Zheng, Huang and Li.

Entities:  

Keywords:  adjuvant chemotherapy; fecal occult blood test; gastric cancer; prognosis; tumor immune microenvironment

Year:  2021        PMID: 33643891      PMCID: PMC7905191          DOI: 10.3389/fonc.2020.526746

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  48 in total

Review 1.  Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer.

Authors:  P Sun; J-B Xiang; Z-Y Chen
Journal:  Br J Surg       Date:  2009-01       Impact factor: 6.939

2.  Impact of the Charlson comorbidity index and prognostic nutritional index on prognosis in patients with early gastric cancer after endoscopic submucosal dissection.

Authors:  Naoto Iwai; Osamu Dohi; Yuji Naito; Yutaka Inada; Akifumi Fukui; Shun Takayama; Kazuyuki Ogita; Kei Terasaki; Takahiro Nakano; Tomohiro Ueda; Tetsuya Okayama; Naohisa Yoshida; Kazuhiro Katada; Kazuhiro Kamada; Kazuhiko Uchiyama; Takeshi Ishikawa; Osamu Handa; Tomohisa Takagi; Hideyuki Konishi; Nobuaki Yagi; Yoshito Itoh
Journal:  Dig Endosc       Date:  2018-04-11       Impact factor: 7.559

3.  Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors.

Authors:  Miro Viitala; Reetta Virtakoivu; Sina Tadayon; Jenna Rannikko; Sirpa Jalkanen; Maija Hollmén
Journal:  Clin Cancer Res       Date:  2019-02-12       Impact factor: 12.531

4.  Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection.

Authors:  Ji Yeong An; Hyunki Kim; Jae-Ho Cheong; Woo Jin Hyung; Hoguen Kim; Sung Hoon Noh
Journal:  Int J Cancer       Date:  2011-11-19       Impact factor: 7.396

5.  Laparoscopic Suprapancreatic Lymph Node Dissection for Advanced Gastric Cancer Using a Left-Sided Approach.

Authors:  Chang-Ming Huang; Qi-Yue Chen; Jian-Xian Lin; Chao-Hui Zheng; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Xin-Tao Yang
Journal:  Ann Surg Oncol       Date:  2015-01-22       Impact factor: 5.344

6.  Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.

Authors:  Yoon Young Choi; Hyunki Kim; Su-Jin Shin; Ha Yan Kim; Jinae Lee; Han-Kwang Yang; Woo Ho Kim; Young-Woo Kim; Myeong-Cherl Kook; Young Kyu Park; Hyung-Ho Kim; Hye Seung Lee; Kyung Hee Lee; Mi Jin Gu; Seung Ho Choi; SoonWon Hong; Jong Won Kim; Woo Jin Hyung; Sung Hoon Noh; Jae-Ho Cheong
Journal:  Ann Surg       Date:  2019-08       Impact factor: 12.969

7.  A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult.

Authors:  B Towler; L Irwig; P Glasziou; J Kewenter; D Weller; C Silagy
Journal:  BMJ       Date:  1998-08-29

8.  Correlations of hemoglobin index (IHb) of gastric mucosa with Helicobacter pylori (H. pylori) infection and inflammation of gastric mucosa.

Authors:  K Uchiyama; K Ida; J Okuda; Y Asai; Y Ohyama; M Kuroda; N Matsumoto; T Takami; T Ogawa; K Takaori
Journal:  Scand J Gastroenterol       Date:  2004-11       Impact factor: 2.423

9.  Gene expression profiles for a prognostic immunoscore in gastric cancer.

Authors:  D Zeng; R Zhou; Y Yu; Y Luo; J Zhang; H Sun; J Bin; Y Liao; J Rao; Y Zhang; W Liao
Journal:  Br J Surg       Date:  2018-04-25       Impact factor: 6.939

10.  Occult blood in faeces is associated with all-cause and non-colorectal cancer mortality.

Authors:  Gillian Libby; Callum G Fraser; Frank A Carey; David H Brewster; Robert J C Steele
Journal:  Gut       Date:  2018-07-16       Impact factor: 23.059

View more
  1 in total

1.  Cause of Death, Mortality and Occult Blood in Colorectal Cancer Screening.

Authors:  Lasse Kaalby; Issam Al-Najami; Ulrik Deding; Gabriele Berg-Beckhoff; Robert J C Steele; Morten Kobaek-Larsen; Aasma Shaukat; Morten Rasmussen; Gunnar Baatrup
Journal:  Cancers (Basel)       Date:  2022-01-04       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.